Self-reported benefit and weakness after botulinum toxin in dystonia

Panagiotis Kassavetis; Codrin Lungu; Debra Ehrlich; Katharine Alter; Barbara I Karp

doi:10.1016/j.parkreldis.2020.08.035

Self-reported benefit and weakness after botulinum toxin in dystonia

Parkinsonism Relat Disord. 2020 Nov:80:10-11. doi: 10.1016/j.parkreldis.2020.08.035. Epub 2020 Aug 30.

Authors

Panagiotis Kassavetis¹, Codrin Lungu², Debra Ehrlich³, Katharine Alter⁴, Barbara I Karp²

Affiliations

¹ NIH/NINDS, Human Motor Control Section, Bethesda, MD, United States. Electronic address: panagiotis.kassavetis@nih.gov.
² NIH/NINDS, Division of Clinical Research, Bethesda, MD, United States.
³ NIH/NINDS, Parkinson's Disease Clinic, Office of the Clinical Director, Bethesda, MD, United States.
⁴ NIH, Rehabilitation Medicine Department, Clinical Center, Bethesda, MD, United States.

PMID: 32927341
DOI: 10.1016/j.parkreldis.2020.08.035

Abstract

With this retrospective, single center, chart review study, we investigate the self-reported benefit and weakness after botulinum toxin injections in three different types of dystonia: focal hand dystonia (FHD), blepharospasm and cervical dystonia. We found that the benefit lasts significantly longer in FHD compared to the other two groups.

Keywords: Botulinum toxin; Dystonia.

Published by Elsevier Ltd.

Publication types

Letter
Research Support, N.I.H., Intramural

MeSH terms

Aged
Blepharospasm / drug therapy*
Botulinum Toxins / administration & dosage
Botulinum Toxins / pharmacology*
Dystonic Disorders / drug therapy*
Female
Humans
Male
Middle Aged
Patient Reported Outcome Measures*
Retrospective Studies
Self Report
Torticollis / drug therapy*

Substances

Botulinum Toxins

Supplementary concepts

Dystonia, Focal, Task-Specific